2021
Multicenter, randomized, double‐blinded, placebo‐controlled study of rabacfosadine in dogs with lymphoma
Weishaar K, Wright Z, Rosenberg M, Post G, McDaniel J, Clifford C, Phillips B, Bergman P, Randall E, Avery A, Thamm D, Hull A, Gust C, Donoghue A. Multicenter, randomized, double‐blinded, placebo‐controlled study of rabacfosadine in dogs with lymphoma. Journal Of Veterinary Internal Medicine 2021, 36: 215-226. PMID: 34952995, PMCID: PMC8783351, DOI: 10.1111/jvim.16341.Peer-Reviewed Original ResearchConceptsBest overall response ratePlacebo-treated dogsProgression-free survivalOverall response rateAdverse eventsResponse rateMedian progression-free survivalCommon adverse eventsPlacebo-controlled studySerious adverse eventsNovel chemotherapy agentsClient-owned dogsTreatment of lymphomaRAB groupSignificant antitumor efficacyStudy endpointMulticentric lymphomaTreatment completionChemotherapy agentsPercent progressionSafety dataLast treatmentClinical importanceLymphomaRabacfosadine
2020
Concurrent use of rabacfosadine and L‐asparaginase for relapsed or refractory multicentric lymphoma in dogs
Cawley J, Wright Z, Meleo K, Post G, Clifford C, Vickery K, Vail D, Bergman P, Thamm D. Concurrent use of rabacfosadine and L‐asparaginase for relapsed or refractory multicentric lymphoma in dogs. Journal Of Veterinary Internal Medicine 2020, 34: 882-889. PMID: 32064697, PMCID: PMC7096650, DOI: 10.1111/jvim.15723.Peer-Reviewed Original ResearchConceptsMedian progression-free survival timeOverall response rateComplete responseMulticentric lymphomaAdverse eventsL-asparaginaseProspective single-arm clinical trialProgression-free survival timeSingle-arm clinical trialNegative prognostic factorRelapse of lymphomaTreatment of lymphomaNovel antineoplastic agentPrognostic factorsChemotherapy protocolsClinical trialsRabacfosadineSurvival timeIU/Response rateClinical importanceLymphomaMultivariate analysisAntineoplastic agentsConcurrent use
2017
Geographical differences in survival of dogs with non‐Hodgkin lymphoma treated with a CHOP based chemotherapy protocol
Wilson‐Robles H, Budke C, Miller T, Dervisis N, Novosad A, Wright Z, Thamm D, Vickery K, Burgess K, Childress M, Lori J, Saba C, Rau S, Silver M, Post G, Reeds K, Gillings S, Schleis S, Stein T, Brugmann B, DeRegis C, Smrkovski O, Lawrence J, Laver T. Geographical differences in survival of dogs with non‐Hodgkin lymphoma treated with a CHOP based chemotherapy protocol. Veterinary And Comparative Oncology 2017, 15: 1564-1571. PMID: 28419683, DOI: 10.1111/vco.12302.Peer-Reviewed Original ResearchConceptsProgression-free survivalFree survivalMultivariable Cox regression modelsShorter progression-free survivalSurvival of dogsCox regression modelNon-Hodgkin lymphomaCHOP chemotherapyChemotherapy protocolsReferral institutionMedical recordsUnivariate analysisDoxorubicin dosesCanine lymphomaVeterinary oncologyDoxorubicin treatmentGeographical differencesLymphomaDogsSignificant differencesImmunophenotypeSurvivalRegression modelsGeographic differencesUS regions
2009
Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP‐MA) for the treatment of canine lymphoma
Daters A, Mauldin G, Mauldin G, Brodsky E, Post G. Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP‐MA) for the treatment of canine lymphoma. Veterinary And Comparative Oncology 2009, 8: 11-22. PMID: 20230577, DOI: 10.1111/j.1476-5829.2009.00199.x.Peer-Reviewed Original ResearchConceptsMultidrug chemotherapy protocolMulticentric lymphomaMedian survivalChemotherapy protocolsSurvival timeOverall median survivalDose of doxorubicinCanine multicentric lymphomaMitoxantrone dosesOverall remissionSteroid administrationMedian remissionHistorical controlsRemission timeCanine lymphomaLymphomaRemissionMitoxantroneDogsFurther studiesL-asparaginaseSurvivalDoxorubicinDaysHypercalcaemiaAsparaginase and MOPP Treatment of Dogs with Lymphoma
Brodsky E, Maudlin G, Lachowicz J, Post G. Asparaginase and MOPP Treatment of Dogs with Lymphoma. Journal Of Veterinary Internal Medicine 2009, 23: 578-584. PMID: 19645842, DOI: 10.1111/j.1939-1676.2009.0289.x.Peer-Reviewed Original ResearchConceptsOverall survival timeT-cell lymphomaT-cell phenotypeEntire study populationStudy populationSurvival timeMulticentric T-cell lymphomaMedian overall survival timeProgression-free survival timePresence of hypercalcemiaOverall response rateReferral veterinary hospitalAntigen receptor rearrangementMedian PFSMOPP chemotherapyMOPP treatmentPrevious chemotherapyLonger PFSChemotherapy protocolsMulticentric lymphomaRetrospective studyPolymerase chain reactionCytologic diagnosisReceptor rearrangementLymphoma